Helix Net Income From Continuing Ops from 2010 to 2026
| HBP Stock | CAD 1.84 0.01 0.54% |
Net Loss | First Reported 2017-01-31 | Previous Quarter -1.5 M | Current Value -1 M | Quarterly Volatility 781.6 K |
Check Helix BioPharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Helix BioPharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.6 K, Interest Expense of 8.6 K or Selling General Administrative of 2.7 M, as well as many indicators such as Price To Sales Ratio of 20.62, Dividend Yield of 0.0 or PTB Ratio of 4.62. Helix financial statements analysis is a perfect complement when working with Helix BioPharma Valuation or Volatility modules.
Helix | Net Income From Continuing Ops |
Evaluating Helix BioPharma's Net Income From Continuing Ops across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Helix BioPharma Corp's fundamental strength.
Latest Helix BioPharma's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Helix BioPharma Corp over the last few years. It is Helix BioPharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Helix BioPharma's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Helix Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (9,112,405) | |
| Coefficient Of Variation | (17.42) | |
| Mean Deviation | 1,131,840 | |
| Median | (8,780,000) | |
| Standard Deviation | 1,587,572 | |
| Sample Variance | 2.5T | |
| Range | 6.6M | |
| R-Value | 0.10 | |
| Mean Square Error | 2.7T | |
| R-Squared | 0.01 | |
| Significance | 0.69 | |
| Slope | 32,938 | |
| Total Sum of Squares | 40.3T |
Helix Net Income From Continuing Ops History
About Helix BioPharma Financial Statements
Helix BioPharma investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Helix Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -10.7 M | -11.2 M |
Pair Trading with Helix BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Helix BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Helix BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving against Helix Stock
| 0.75 | HD | Home Depot CDR | PairCorr |
| 0.47 | BCE-PT | Bce Inc Pref | PairCorr |
| 0.44 | DNG | Dynacor Gold Mines | PairCorr |
| 0.38 | CRE | Critical Elements | PairCorr |
| 0.36 | HSTR | Heliostar Metals | PairCorr |
The ability to find closely correlated positions to Helix BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Helix BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Helix BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Helix BioPharma Corp to buy it.
The correlation of Helix BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Helix BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Helix BioPharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Helix BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Helix Stock
Helix BioPharma financial ratios help investors to determine whether Helix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.